|

Very preliminary overview of comparative effectiveness eric caplan, biopractices, mark goldberger, abbott labs

The Impact of Specialty Treatments:
Preparing for a Tsunami?
Cary Sennett, MD, PhD, FACP
President and CEO
Asthma and Allergy Foundation of America
for life without limits™ ABOUT AAFA
 501c3 dedicated to improving the lives of people with asthma and allergic disease  Serves as the "voice of the patient" in national and state-level policy conversations (like today's)  Serves to educate and inform that voice through educational content  Increasingly involved in research—and the intersection of research, policy, and education for life without limits™

AAFA PUBLIC AWARENESS
 Awareness Campaigns – PSAs, rankings,
seasonal
 Certification Program – healthy home
 Web Site – 3 million unique visit visitors per year
 Social Networks – Kids With Food Allergy (KFA),
FB, Twitter, Inspire and Causes
 Publications – newsletters, product guides
 Information and Materials – flyers, brochures
 Toll-free Hotline: 1-800-7-ASTHMA
 National Asthma & Allergy Awareness Month™
www.aafa.org for life without limits™

AAFA RESEARCH REPORTS
 Asthma Capitals™ – An annual analysis of
metro area asthma data that ranks the largest
cities in the U.S. with respect to their success at
achieving important outcomes for people with
 State Honor Roll – An annual report that
identifies states with the most comprehensive
and effective public policies supporting people
with asthma, food allergies, anaphylaxis, and
related allergic diseases in U.S. elementary,
middle, and high schools.
for life without limits™ AAFA PUBLIC POLICY
 Improve Access to Care
 Health care that covers everyone, curbs costs responsibly, abolishes
exclusions for pre-existing conditions, eliminates lifetime caps, and
ensures long-term and end-of-life care
 Efforts to cover all uninsured children in the US to address health care
disparities
 Access to safe, effective treatments for asthma and allergies that best
meet the patients' interests
 Increase Funding for Federal Research
 Support maximizing basic, clinical, preventive and health services
research funding relevant to asthma and allergic diseases
 Promote Prevention
 Support efforts to prevent asthma and allergies from developing and
worsening the health of Americans, including strategies to reduce risks
in the home, workplace, school and the environme
for life without limits™ ABOUT ASTHMA
 Prevalent
 Morbid and mortal
 Care is costly—and inefficient
 Disproportionately affects
vulnerable populations
 No cure
 Manageable—but challenging
 Access to medication is
important
 Access to medication is not
ALL that's important

for life without limits™

OF COURSE PEOPLE WITH ASTHMA WANT ACCESS TO
AFFORDABLE MEDICATIONS—BUT WHAT THEY REALLY WANT IS:
THEY WANT TO LIVE LIVES NOT LIMITED BY THEIR HEALTH
for life without limits™ TO LIVE THAT LIFE WITHOUT LIMITS, PEOPLE WITH ASTHMA
RELY ON A COMBINATION OF MEDICINES, DEVICES, AND LIFE
STYLE MODIFICATIONS
for life without limits™ THE GOOD NEWS IS THE PRICE OF MANY OF THESE MEDICATIONS
IS DECLINING IN THE WAKE OF GENERIC SUBSTITUTIONS
New generic Singulair could save asthma sufferers big
bucks
… within the first year or so, the
Consumer Reports News: August 06, 2012 05:37 PM
Asthma and allergy sufferers who take Singulair (montelukast) will soon be able to monthly cost of the generic is
slash their medication bills. Late last week, the Food and Drug Administration approved the first generic version of the popular drug. And within the first year or so, expected to drop to half or less of
the monthly cost of the generic is expected to drop to half or less of the $180 retail price tag of brand-name Singulair. the $180 retail price tag of brand-
If you're one of the millions of people who take Singular, you're probably wondering name Singulair.
when you will see the price tumble even further on the generic. The short answer is, it's uncertain. Sometimes it can take several months following a generic approval before consumers see substantial price reductions. This happens because often, only one generic manufacturer has been allowed to produce the drug in the first six months, so there is no competition to drive the price down. But with Singulair, the price drop should happen sooner since the FDA granted 10 manufacturers the right to make a generic version. At least one of the 10 has already started shipping its generic to pharmacies, and the others will likely soon follow. Montelukast, the generic name of the medication in Singulair, helps reduce asthma and allergy symptoms by blocking substances in the body called leukotrienes that can trigger inflammation and constrict airways. The most common side effects of the drug include fever, headache, cough, diarrhea, runny nose and sinus infections. In rare cases, the medication can also cause serious side effects. Contact your doctor immediately if you experience any of these while taking montelukast: mood changes, such as aggression, depression, or hallucinations; a feeling of "pins and needles" or numbness in the arms or legs; a rash; flu-like symptoms; or severe pain and swelling of the sinuses. for life without limits™ BUT THERE IS A TSUNAMI COMING
for life without limits™ BUT THERE IS A TSUNAMI COMING
for life without limits™ BUT THERE IS A TSUNAMI COMING
for life without limits™ THE GOAL AND PATH FORWARD
People with asthma will have access to
effective medication at a reasonable cost

 Need policies that assures access to the most effective option
for each individual

 Need research to create a better map between individuals and
therapies

 Need patients to engage more effectively
 And we need to be careful, so that we do not stifle the R&D
needed, to solve the access problem for those for whom there
are not yet effective medications (at any cost)
for life without limits™  Drug costs are a problem—and are likely to be more so in
the near future
 Addressing that problem will require policy that assures
that patients have access to the medications that are right
for them
 That kind of "precision medicine" will require research
 Improving lives for people with asthma requires more than
policy and research
 Patient engagement is essential
 Patients need support to engage
 Savings—from better outcomes—can help offset
potentially higher medication costs
for life without limits™ FOR MORE INFORMATION
 Contact me: Cary Sennett, MD, PhD, FACP:  Contact Meryl Bloomrosen, SVP for Policy, Advocacy and Research:  Contact AAFA: or for life without limits™

Source: http://www.csrxp.org/wp-content/uploads/2015/04/NCHC_Sennett._for_distribution._final.pdf